"Survodutide: A Promising Competitor in the Weight-Loss Drug Market"
TL;DR
Zealand Pharma's stock surged over 34% after positive results in a clinical trial for a liver disease drug that also shows promise for weight loss, potentially challenging market leaders Novo Nordisk and Eli Lilly. Novo Nordisk's sales are projected to increase by up to 26% in 2024 due to the demand for weight loss drugs like Wegovy and Ozempic, with the potential for the company to become one of the first trillion-dollar pharmaceutical companies. Competition in the weight loss drug market is intensifying, with several companies, including Regeneron, Amgen, and Viking Pharmaceuticals, racing to introduce new drugs to compete with the current market leaders.
Topics:businesshealth-and-pharmaceuticals#clinical-trial#competition#health-and-pharmaceuticals#novo-nordisk#pharmaceutical-companies#weight-loss-drug
- Ozempic, Wegovy competitor emerges for weight loss drugs in Zealand Pharma Quartz
- Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug results CNBC
- Boehringer’s Obesity Candidate Survodutide Shows Strong Potential in MASH BioSpace
- Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Yahoo Finance
- Biotech Stocks Diverge On New Results For Weight-Loss Drug In MASH Patients Investor's Business Daily
Want the full story? Read the original reporting
Read on Quartz